Terms: = Liver cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
67 results:
1. Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma.
Ahmad F; Ma L; Wei W; Liu Y; Hakim I; Daugherty A; Mujahid S; Radin AA; Chua MS; So S
Liver Int; 2023 Dec; 43(12):2794-2807. PubMed ID: 37833852
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacological inhibition of mek1/2 signaling disrupts bile acid metabolism through loss of Shp and enhanced Cyp7a1 expression.
Verzijl CRC; van de Peppel IP; Eilers RE; Bloks VW; Wolters JC; Koehorst M; Kloosterhuis NJ; Havinga R; Jalving M; Struik D; Jonker JW
Biomed Pharmacother; 2023 Mar; 159():114270. PubMed ID: 36680812
[TBL] [Abstract] [Full Text] [Related]
3. Cobimetinib Plus Vemurafenib in Patients With Colorectal cancer With
Klute KA; Rothe M; Garrett-Mayer E; Mangat PK; Nazemzadeh R; Yost KJ; Duvivier HL; Ahn ER; Cannon TL; Alese OB; Krauss JC; Thota R; Calfa CJ; Denlinger CS; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Nov; 6():e2200191. PubMed ID: 36409971
[TBL] [Abstract] [Full Text] [Related]
4. CircNFIB inhibits tumor growth and metastasis through suppressing mek1/ERK signaling in intrahepatic cholangiocarcinoma.
Du J; Lan T; Liao H; Feng X; Chen X; Liao W; Hou G; Xu L; Feng Q; Xie K; Liao M; Chen X; Huang J; Yuan K; Zeng Y
Mol Cancer; 2022 Jan; 21(1):18. PubMed ID: 35039066
[TBL] [Abstract] [Full Text] [Related]
5. Activation of ERK and p38 Reduces AZD8055-Mediated Inhibition of Protein Synthesis in Hepatocellular Carcinoma HepG2 Cell Line.
Jee HY; Lee YG; Lee S; Elvira R; Seo HE; Lee JY; Han J; Lee K
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769253
[TBL] [Abstract] [Full Text] [Related]
6. Clinical study of map2k1-mutated Langerhans cell histiocytosis in children.
Yang Y; Wang C; Wang D; Cui L; Li N; Lian H; Ma H; Zhao Y; Zhang L; Liu W; Wang Y; Wu W; Zhang R; Li Z; Wang T
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2517-2527. PubMed ID: 34595543
[TBL] [Abstract] [Full Text] [Related]
7. Clinical features and treatment of Langerhans cell histiocytosis.
Rodriguez-Galindo C
Acta Paediatr; 2021 Nov; 110(11):2892-2902. PubMed ID: 34192374
[TBL] [Abstract] [Full Text] [Related]
8. Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism.
Zhao X; Wang J; Deng Y; Liao L; Zhou M; Peng C; Li Y
Phytother Res; 2021 Sep; 35(9):4727-4747. PubMed ID: 34159683
[TBL] [Abstract] [Full Text] [Related]
9. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
[TBL] [Abstract] [Full Text] [Related]
10. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.
Reddy D; Kumavath R; Tan TZ; Ampasala DR; Kumar AP
Life Sci; 2020 Jan; 241():117147. PubMed ID: 31830480
[TBL] [Abstract] [Full Text] [Related]
11. Trametinib in the treatment of multiple malignancies harboring mek1 mutations.
Lian T; Li C; Wang H
Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
[TBL] [Abstract] [Full Text] [Related]
12. Litchi (Litchi chinensis Sonn.) flower proanthocyanidin fraction exhibited protective efficacy to suppress nickel-induced expression for vascular endothelial growth factor in HepG2 cells.
Lin JT; Chang YY; Chen YC; Liao PL; Yang DJ
J Food Biochem; 2019 Jul; 43(7):e12882. PubMed ID: 31353727
[TBL] [Abstract] [Full Text] [Related]
13. Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib.
Wei CT; Chen LC; Hsiang YP; Hung YJ; Chien PH; Pan HL; Chen YJ
Anticancer Res; 2019 Feb; 39(2):695-701. PubMed ID: 30711947
[TBL] [Abstract] [Full Text] [Related]
14. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.
Wang C; Jin H; Gao D; Lieftink C; Evers B; Jin G; Xue Z; Wang L; Beijersbergen RL; Qin W; Bernards R
J Hepatol; 2018 Nov; 69(5):1057-1065. PubMed ID: 30030148
[TBL] [Abstract] [Full Text] [Related]
15. Cinobufacini inhibits epithelial-mesenchymal transition of human hepatocellular carcinoma cells through c-Met/ERK signaling pathway.
Qi F; Wang J; Zhao L; Cai P; Tang W; Wang Z
Biosci Trends; 2018 Jul; 12(3):291-297. PubMed ID: 29794405
[TBL] [Abstract] [Full Text] [Related]
16. Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of mek1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells.
Ding Y; Chen X; Wang B; Yu B; Ge J; Shi X
Can J Physiol Pharmacol; 2018 May; 96(5):521-526. PubMed ID: 29394494
[TBL] [Abstract] [Full Text] [Related]
17. (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways.
Satonaka H; Ishida K; Takai M; Koide R; Shigemasa R; Ueyama J; Ishikawa T; Hayashi K; Goto H; Wakusawa S
Anticancer Res; 2017 Nov; 37(11):6071-6077. PubMed ID: 29061787
[TBL] [Abstract] [Full Text] [Related]
18. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via mek1/ERK/ELK1 signaling in hepatocellular carcinoma.
Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
[TBL] [Abstract] [Full Text] [Related]
19. Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.
Lin B; Zhou X; Lin S; Wang X; Zhang M; Cao B; Dong Y; Yang S; Wang JM; Guo M; Huang J
J Mol Med (Berl); 2017 Nov; 95(11):1237-1249. PubMed ID: 28844099
[TBL] [Abstract] [Full Text] [Related]
20. β-mangostin suppresses human hepatocellular carcinoma cell invasion through inhibition of MMP-2 and MMP-9 expression and activating the ERK and JNK pathways.
Huang CF; Teng YH; Lu FJ; Hsu WH; Lin CL; Hung CC; Tung JN; Hsieh YH; Liu CJ
Environ Toxicol; 2017 Nov; 32(11):2360-2370. PubMed ID: 28722351
[TBL] [Abstract] [Full Text] [Related]
[Next]
